A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Bemcentinib (Primary) ; Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors BerGenBio
- 29 Jan 2018 According to a BerGenBio media release, data from this study is presented at the ASCO-SITC Clinical Immuno-Oncology Symposium 2018.
- 17 Nov 2017 According to a BerGenBio media release, first patient has been dosed.
- 25 Sep 2017 Status changed from not yet recruiting to recruiting.